Clinical Trials Logo

Mitochondrial Myopathy clinical trials

View clinical trials related to Mitochondrial Myopathy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02895789 Completed - Clinical trials for Spinal Muscular Atrophy Type 3

Oxidative Capacity and Exercise Tolerance in Ambulatory SMA

Start date: November 2016
Phase:
Study type: Observational

This proposal will focus on (1) estimating oxidative capacity of specific muscle groups during exercise using near infrared spectroscopy and (2) describing body composition to better understand exercise capacity and mitochondrial function in ambulatory spinal muscular atrophy (SMA) patients and disease controls. It is a 6-month observational study including 14 ambulatory SMA patients, 14 ambulatory patients with mitochondrial myopathy, and 14 healthy controls.

NCT ID: NCT02367014 Completed - Clinical trials for Mitochondrial Myopathy

Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy

MMPOWER
Start date: February 2015
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2, multi-center, randomized, double-blind, multiple ascending dose, placebo-controlled study that enrolled 36 subjects with mitochondrial myopathy associated with genetically confirmed mitochondrial disease to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MTP-131 in this patient population.

NCT ID: NCT00004770 Completed - Clinical trials for Mitochondrial Myopathy

Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy

Start date: October 1995
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Assess the efficacy of thioctic acid in treating a single patient with mitochondrial myopathy.

NCT ID: NCT00004353 Completed - Lactic Acidosis Clinical Trials

Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia

Start date: December 1978
Phase: N/A
Study type: Observational

OBJECTIVES: I. Study the metabolism of pyruvate and related problems in patients with lactic acidemia. II. Define the nature of the metabolic defect.